timothy p coughlin  amsterdam ny  intelius sign in we found timothy p coughlin in amsterdam ny timothy p coughlin intelius found that timothy p coughlin is a male between  and  years old from amsterdam ny we have connected them to  addresses  phones and  relatives or associates get report now age timothy p coughlin is in his s timothy has lived in amsterdam ny tribes hill ny albany ny timothy p coughlin zodiac signcancer gendermale professional status chief executive officer at payroll plus get report now want to know more about timothy get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about timothy or use our people search engine to find others get background check on timothy p coughlin get a criminal check on timothy p coughlin get a public record report on timothy p coughlin get a people search report on timothy p coughlin timothy p coughlins contact information known cities lived in find out where timothy p coughlin has lived as well as timothy p coughlins phone numbers and email addresses timothy p coughlin has lived in  states new york address for timothy p coughlin  f p amsterdam ny has lived in amsterdam ny tribes hill ny get full address report phone numbers associated with timothy p coughlin    amsterdam ny    albany ny get full phone report email addresses associated with timothy p coughlin cycom get email report timothy p coughlins professional information information regarding timothy p coughlins professional history find out previous places timothy p coughlin has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act timothy p coughlin has worked at  place company payroll plus title chief executive officer timothy p coughlins experience title chief executive officer company payroll plus job details additional professional information on timothy p coughlin see timothy p coughlins linkedin profile timothy p coughlins social network and potential email matches find out potential social network profiles and potential email usernamed for timothy p coughlin timothy p coughlins known social networks and potential email matches find all of timothy p coughlins social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches timothy coughlin username matches timothycoughlin coughlintimothy timothycoughlin coughlintimothy timothycoughlin coughlintimothy timothycoughlin coughlintimothy tcoughlin popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches t coughlin intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here timmy p coughlin  amherst oh  intelius sign in we found timmy p coughlin in amherst oh timmy p coughlin intelius found that timmy p coughlin is a male between  and  years old from amherst oh we have connected them to  address  phones and  relatives or associates also known as timothy p coughlin tim coughlin get report now age timmy p coughlin is in his s timmy has lived in amherst oh timmys relatives ryan coughlin helen coughlin mark coughlin stephen coughlin timmy p coughlin zodiac signaquarius gendermale professional status assistant supervisor of commissions at commonwealth of massachusetts get report now want to know more about timmy get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about timmy or use our people search engine to find others get background check on timmy p coughlin get a criminal check on timmy p coughlin get a public record report on timmy p coughlin get a people search report on timmy p coughlin timmy p coughlins contact information known cities lived in find out where timmy p coughlin has lived as well as timmy p coughlins phone numbers and email addresses timmy p coughlin has lived in  states ohio address for timmy p coughlin  a d amherst oh has lived in amherst oh get full address report phone numbers associated with timmy p coughlin    amherst oh    amherst oh get full phone report email addresses associated with timmy p coughlin get email report timmy p coughlins professional information information regarding timmy p coughlins professional history find out previous places timmy p coughlin has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act timmy p coughlin has worked at  place company commonwealth of massachusetts title assistant supervisor of commissions timmy p coughlins experience title assistant supervisor of commissions company commonwealth of massachusetts job details additional professional information on timmy p coughlin see timmy p coughlins linkedin profile timmy p coughlins social network and potential email matches find out potential social network profiles and potential email usernamed for timmy p coughlin timmy p coughlins known social networks and potential email matches find all of timmy p coughlins social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches timmy coughlin username matches timmycoughlin coughlintimmy timmycoughlin coughlintimmy timmycoughlin coughlintimmy timmycoughlin coughlintimmy tcoughlin popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches t coughlin intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here neurocrine biosciences announces chief financial officer timothy p coughlin to step down data stocks events calendar sectors investment strategies etfs cefs mutual funds indices economic indicators economic calendar news tools dashboard fundamental chart technical chart equity screener fund screener comp tables timeseries analysis excel api support support topics contact us terms of use privacy policy about us careers financial glossary plans free trial sign in free trial sign in data stocks events calendar sectors investment strategies etfs cefs mutual funds indices economic indicators economic calendar news tools dashboard fundamental chart technical chart equity screener fund screener comp tables timeseries analysis excel api support support topics contact us terms of use privacy policy about us careers financial glossary plans free trial sign in free trial sign in neurocrine biosciences announces chief financial officer timothy p coughlin to step down will continue to support company over extended transition period through end of  december    san diego dec   prnewswire  neurocrine biosciences inc nasdaq nbix a biotechnology company focused on neurological and endocrine related disorders announced today that timothy p coughlin will be stepping down from his position as chief financial officer in midfebruary for personal reasons the board has initiated a replacement search and mr coughlin has agreed to continue with the company through  to facilitate a smooth transition of responsibilitieson behalf of the board shareholders and our employees i want to thank tim for his over ten years of tireless service as cfo of neurocrine said dr kevin c gorman president and chief executive officer of neurocrine tim has been a tremendous person to work with and a key part of the team which orchestrated the turnaround of neurocrine i am very pleased that we will continue to work together through a transition period through his leadership we are in a strong financial position that allows us to continue to execute on our commercialization and clinical plansdeciding to leave neurocrine was an extremely difficult decision for me i am incredibly proud of the biotechnology company we have built and the promising therapies the company has and continues to develop said mr coughlin i look forward to working through transitioning to a new cfo as well as the next evolution of neurocrine   about neurocrine biosciencesneurocrine biosciences inc discovers and develops innovative and lifechanging pharmaceuticals in diseases with high unmet medical needs through its novel rd platform focused on neurological and endocrine based diseases and disorders the companys two programs are elagolix a gonadotropinreleasing hormone antagonist in phase iii development for womens health that is partnered with abbvie inc and ingrezza a vesicular monoamine transporter  inhibitor for which an nda has been filed with the fda for the treatment of tardive dyskinesia and is in phase ii development for patients with tourette syndrome neurocrine plans to commercialize ingrezza in the united states upon approval of the nda by the fda  neurocrine biosciences inc news releases are available through the companys website via the internet at httpwwwneurocrinecom in addition to historical facts this press release may contain forwardlooking statements that involve a number of risks and uncertainties among the factors that could cause actual results to differ materially from those indicated in the forwardlooking statements are risks and uncertainties associated with neurocrines business and finances in general ingrezza development and commercialization the companys r  d pipeline and the company overall specifically the risks and uncertainties the company faces include risks that the companys product candidates may not obtain regulatory approval or that the us food and drug administration or regulatory authorities outside the us may make adverse decisions regarding the companys product candidates risks that clinical development activities may not be completed on time or at all risks that clinical development activities may be delayed for regulatory or other reasons may not be successful or replicate previous clinical trial results may fail to demonstrate that our product candidates are safe and effective or may not be predictive of realworld results or of results in subsequent clinical trials risks that the companys product candidates may be precluded from commercialization by the proprietary rights of third parties or have unintended side effects adverse reactions or incidents of misuse risks associated with the companys dependence on third parties for development manufacturing and marketing activities risks that the companys research programs will not identify preclinical candidates for further development risks that the company will be unable to raise additional funding required to complete development of all of its product candidates risk and uncertainties relating to competitive products and technological changes that may limit demand for the companys products and other risks described in the companys quarterly report on form q for the quarter ended september   neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesneurocrinebiosciencesannounceschieffinancialofficertimothypcoughlintostepdownhtmlsource neurocrine biosciences inc related stories chief executive officer gorman kevin charles exer acquires k of nbix on  mt newswires   et mt newswires afterhours news movers mt newswires   et neurocrine bio fiance chief to step down in midfebruary sa breaking news   et neurocrine biosciences cfo timothy p coughlin resigns mt newswires   et neurocrine biosciences announces chief financial officer timothy p coughlin to step down pr newswire   et healthcare stocks on investors radar  sophiris bio catalyst pharma neurocrine biosciences and capital senior living pr newswire   et neurocrine biosciences to present at the  bmo capital markets prescription for success healthcare conference pr newswire   et new collaborations and licensing activities for biotechpharma industries pick up pace heading into  pr newswire   et neurocrine biosciences presenting longterm data on potential new treatment for tardive dyskinesia mt newswires   et neurocrine biosciences announces ingrezza™ valbenazine longterm data to be presented at the th annual meeting of the american college of neuropsychopharmacology pr newswire   et advertisement  no credit card required already a subscriber sign in atyr pharma announces appointment of timothy p coughlin to its board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       atyr pharma announces appointment of timothy p coughlin to its board of directors tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs san diego april   globe newswire  atyr pharma inc nasdaqlife a biotherapeutics company engaged in the discovery and development of physiocrinebased therapeutics to address severe rare diseases today announced the appointment of timothy p coughlin to its board of directors mr coughlin served as chief financial officer of neurocrine biosciences from september  to february  mr coughlin brings to the board his extensive background in financial and accounting matters for public companies and leadership experience with highgrowth clinical stage companies in the biotechnology industry“this is an exciting time for atyr” said mr coughlin “atyr has a unique approach to pharmaceutical development given its leadership position in physiocrinebased product biology across three important therapeutic areas i look forward to contributing to atyr potentially bringing these highly innovative products to patients”“we are incredibly pleased to welcome mr coughlin to our board of directors” said john mendlein phd ceo “tim’s industry expertise makes him an excellent addition for atyr as a board member with over a decade in leadership at neurocrine biosciences tim’s experience will provide valuable guidance as we create longterm value for our stockholders” about timothy p coughlin timothy p coughlin served as chief financial officer of neurocrine biosciences inc from september  to february  where he previously served as vice president controller prior to joining neurocrine in  he was with catholic health initiatives a nationwide integrated healthcare delivery system where he served as vice president financial services mr coughlin also served as a senior manager in the health sciences practice of ernst  young llp and its predecessors from  to  mr coughlin currently serves on the board of directors of retrophin inc and fate therapeutics inc two biotechnology companies where he chairs the audit committees and is also a member of the compensation committee and nominating committee  mr coughlin holds a master’s degree from san diego state university and a bachelor’s degree from temple university and is a certified public accountant in both california and pennsylvaniaabout atyr pharma atyr pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology a newly discovered set of physiological pathways to date the company has generated three innovative therapeutic candidate programs based on its knowledge of physiocrine biology in three different therapeutic areas atyr has built an intellectual property estate to protect its pipeline comprising over  issued patents or allowed patent applications that are owned or exclusively licensed including over  potential physiocrinebased protein compositions atyrs key programs are currently focused on severe rare diseases characterized by immune imbalance for which there are currently limited or no treatment options for more information please visit httpwwwatyrpharmacomforwardlooking statementsthis press release contains forwardlooking statements within the meaning of the private litigation reform act  forwardlooking statements are usually identified by the use of words such as “anticipates” “believes” “estimates” “expects” “intends” “may” “plans” “projects” “seeks” “should” “will” and variations of such words or similar expressions we intend these forwardlooking statements to be covered by such safe harbor provisions for forwardlooking statements and are making this statement for purposes of complying with those safe harbor provisions these forwardlooking statements including statements regarding the potential of resolaris™ or stalaris™ the ability of the company to undertake certain development activities such as clinical trial enrollment and the conduct of clinical trials and accomplish certain development goals the timing of initiation of additional clinical trials and of reporting results from our clinical trials and reflect our current views about our plans intentions expectations strategies and prospects which are based on the information currently available to us and on assumptions we have made although we believe that our plans intentions expectations strategies and prospects as reflected in or suggested by those forwardlooking statements are reasonable we can give no assurance that the plans intentions expectations or strategies will be attained or achieved furthermore actual results may differ materially from those described in the forwardlooking statements and will be affected by a variety of risks and factors that are beyond our control including without limitation risks associated with the discovery development and regulation of our physiocrinebased product candidates as well as those set forth in our most recent annual report on form k for the year ended december   and in our other sec filings except as required by law we assume no obligation to update publicly any forwardlooking statements whether as a result of new information future events or otherwisecontact mark johnson sr director investor relations mjohnsonatyrpharmacom  read at biospacecom related news atyr pharma receives ema orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris good salary nice bonus—but why did biotech mogul david hung gamble on axovant axon atyr pharma announces issuance of us patent that extends patent protection of physiocrines derived from  out of  human trna synthetases  things we learned about fda nominee scott gottlieb atyr pharma receives us fda orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris slam fda nominee gottlieb as being too cozy with big pharma to combat opioid epidemic atyr pharma announces fourth quarter and yearend  operating results gottlieb as fda commissioner would be music to pharma’s ears atyr pharma release fda grants fast track designation for companys resolaris to treat limb girdle muscular dystrophy b and removes partial clinical hold for resolaris and hes back medivation mdvns david hung to helm vivek ramaswamys axovant axon please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • atyr pharma inc   • biotechpharma  personnel                 neurocrine biosciences announces chief financial officer timothy p coughlin to step down neurocrine biosciences announces chief financial officer timothy p coughlin to step down will continue to support company over extended transition period through end of  news provided by neurocrine biosciences inc dec    et share this article san diego dec   prnewswire  neurocrine biosciences inc nasdaq nbix a biotechnology company focused on neurological and endocrine related disorders announced today that timothy p coughlin will be stepping down from his position as chief financial officer in midfebruary for personal reasons the board has initiated a replacement search and mr coughlin has agreed to continue with the company through  to facilitate a smooth transition of responsibilities on behalf of the board shareholders and our employees i want to thank tim for his over ten years of tireless service as cfo of neurocrine said dr kevin c gorman president and chief executive officer of neurocrine tim has been a tremendous person to work with and a key part of the team which orchestrated the turnaround of neurocrine i am very pleased that we will continue to work together through a transition period through his leadership we are in a strong financial position that allows us to continue to execute on our commercialization and clinical plans deciding to leave neurocrine was an extremely difficult decision for me i am incredibly proud of the biotechnology company we have built and the promising therapies the company has and continues to develop said mr coughlin i look forward to working through transitioning to a new cfo as well as the next evolution of neurocrine    about neurocrine biosciences neurocrine biosciences inc discovers and develops innovative and lifechanging pharmaceuticals in diseases with high unmet medical needs through its novel rd platform focused on neurological and endocrine based diseases and disorders the companys two programs are elagolix a gonadotropinreleasing hormone antagonist in phase iii development for womens health that is partnered with abbvie inc and ingrezza a vesicular monoamine transporter  inhibitor for which an nda has been filed with the fda for the treatment of tardive dyskinesia and is in phase ii development for patients with tourette syndrome neurocrine plans to commercialize ingrezza in the united states upon approval of the nda by the fda  neurocrine biosciences inc news releases are available through the companys website via the internet at httpwwwneurocrinecom in addition to historical facts this press release may contain forwardlooking statements that involve a number of risks and uncertainties among the factors that could cause actual results to differ materially from those indicated in the forwardlooking statements are risks and uncertainties associated with neurocrines business and finances in general ingrezza development and commercialization the companys r  d pipeline and the company overall specifically the risks and uncertainties the company faces include risks that the companys product candidates may not obtain regulatory approval or that the us food and drug administration or regulatory authorities outside the us may make adverse decisions regarding the companys product candidates risks that clinical development activities may not be completed on time or at all risks that clinical development activities may be delayed for regulatory or other reasons may not be successful or replicate previous clinical trial results may fail to demonstrate that our product candidates are safe and effective or may not be predictive of realworld results or of results in subsequent clinical trials risks that the companys product candidates may be precluded from commercialization by the proprietary rights of third parties or have unintended side effects adverse reactions or incidents of misuse risks associated with the companys dependence on third parties for development manufacturing and marketing activities risks that the companys research programs will not identify preclinical candidates for further development risks that the company will be unable to raise additional funding required to complete development of all of its product candidates risk and uncertainties relating to competitive products and technological changes that may limit demand for the companys products and other risks described in the companys quarterly report on form q for the quarter ended september   neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesneurocrinebiosciencesannounceschieffinancialofficertimothypcoughlintostepdownhtml source neurocrine biosciences inc related links httpwwwneurocrinecom jan    et preview neurocrine biosciences to present at the th annual jp morgan healthcare conference dec    et preview neurocrine biosciences to present at the  bmo capital markets prescription for success healthcare conference my news release contains wide tables view fullscreen also from this source jul    et neurocrine biosciences announces the appointment of julie cooke jun    et neurocrine biosciences to present at the goldman sachs th explore more news releases in similar topics biotechnology health care  hospitals personnel announcements you just read neurocrine biosciences announces chief financial officer timothy p coughlin to step down news provided by neurocrine biosciences inc dec    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search todays stock market news and analysis  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  stock market news todays stock market news  analysis heres why women make great investors by motley fool research shows that women tend to possess these qualities facebooks  profitability will be even better than expected by motley fool investors were particularly encouraged by the companys outlook for expenses this year  of the best classic value stocks you should buy now by zackscom and how to screen for these stocks will nvidias strategy prevail in selfdriving cars by motley fool nvdia can let investors in the game without rolling the dice latest news videos russia ousts us diplomats in sanc amazon posts  revenue spike amid european banks are better investmen bnp paribas cfo waiting to see wha latest news iron mountain to acquire private data center business fortrust  quick facts   am  rtt news appears in world markets us republican effort to gut obamacare ends in defeat for trump   am  reuters appears in stocks nippon steel forecasts annual profit to rise  pct on higher product prices   am  reuters appears in fundamental analysis drilquip inc announces  decline in q profit   am  rtt news appears in politics bombardier reports adjusted quarterly profit   am  reuters appears in stocks russia hits back over sanctions orders us diplomats to leave   am  reuters appears in stocks rpttrump urged washington to stop bank mergers in  letter   am  reuters appears in politics oil extends gains on track for biggest weekly gains this year   am  reuters appears in stocks komatsu q profit soars as china sales double sees pace of growth moderating   am  reuters appears in stocks amid ceasefire rescuers clear unexploded bombs in syrias deraa   am  reuters appears in politics cee marketscrown eases somewhat despite rate hike expectations   am  reuters appears in stocks petronas to take a hit from canada pullout but sees longterm domestic gains   am  reuters appears in stocks euronext posts  pct rise in q core earnings   am  reuters appears in politics hutchisons drei buys tele to rival carlos slim in austria   am  reuters appears in world markets pakistans supreme court ousts pm sharif over corruption claims   am  reuters appears in stocks south africas central bank chief sees return to growth in q   am  reuters appears in stocks emerging marketsemerging stocks fall  pct as wall street tech selloff hits asia   am  reuters appears in world markets chinas ofo in talks to raise  bln led by softbank sources   am  reuters appears in stocks refilesterling steadies close to month high on bets for softer brexit   am  reuters appears in stocks zacks podcast highlights looking for top reit investments start here for your guide   am  zackscom appears in stocks view more headlines browse news by category etfs europe etfs are turning a lot of heads first uslisted bond etfs celebrate year milestone etf strategies to help position for the rest of the year more etfs technology apple discontinues ipod shuffle and nano google hires former webos pebble design lead to work on google home earnings confirm facebook is better investment than twitter more technology commodities technology sector update for  fbshor technology sector update for  ntgr shor pcmi mitl more commodities investing ideas weyerhaeuser wy beats on q earnings lags on revenue valero vlo tops q earnings and revenue estimates notable two hundred day moving average cross  tbph more investing ideas market intelligence stay ahead of the markets with these mustread articles d printing is quietly thriving without mainstream adoption trevir nath nasdaq ndaq nd quarter profit surges more than twofold richard saintvilus an indepth look at baidus bidu artificial intelligence aspirations prableen bajpai stock market today stocks to watch why bristolmyers is tanking featured story from latest articles by martin tillier martin tillers new mustread column on the markets enlightening entertaining every day only at nasdaqcom earnings confirm facebook is better investment than twitter   am eli lilly llys seemingly illogical reaction to earnings beat   am week ahead earnings highlights   am dont count opec out yet   am is fcel setting up for a short squeeze   am more martin tillier closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex timothy j coughlin  thompson hine related sitesproject management consultantscontact usebriefcasecareersattorney careersprofessional staff careers login client extranetclient site newwebmailremote access what the market saysselected by peers for inclusion in the best lawyers in america contact informationcleveland key center public squarecleveland ohio direct fax educationcase western reserve university school of law jd  order of the coifuniversity of notre dame bba  professionals add to ebriefcase timothy j coughlinpartner timcoughlinthompsonhinecomvcard product liability litigationbusiness litigationemerging technologies overviewexperiencepublicationspresentationsdistinctionsprofessional and civicnews overviewtim is chair of our mass  toxic tort group and leads our chemical industry group a multidisciplinary practice group focused on finding creative solutions to our clients concerns and issues in the chemical industry tim is the firms representative to the ohio chemistry technology council and socma he focuses his litigation practice on mass and class action toxic torts product liability and commercial litigation on a national basis tim has represented our clients in over twentythree states and canada tim is the lead counsel for a number of chemical companies and the industry trade association on national litigation involving chemical exposures tim is the  committee chair of the defense research institutes toxic tort environmental law committee committee vice chair  and  and former member of dris corporate counsel roundtable steering committeeexperiencereported cases  ohio supreme court valentine v conrad  ohio st d   michaels v ford motor company  ned  ohio s ct  reported cases  federal circuit and district court taylor v am chemistry council  us app lexis  st cir mass aug   bp chemicals inc v first state insurance co us ct app th cir  us app lexis  maddox v ford motor company us ct app th cir  us app lexis  feistner v ford motor company us ct app th cir  us app lexis  stouffer corp v teachers insurance  annuity assn  fd  th cir  roney v gencorp et al no  judgment order entering jury verdict in favor of defendant sdw va oct   roney v gencorp et al no   us dist lexis  sdw va sept   taylor v airco inc  us dist lexis  hogan v goodrich corp  wl  wd ky jan   bogner v airco inc  f supp d  cd ill  dettinger v chrysler plastic products  us dist ct lexis  reported cases  state court cooper v basf inc et al no  ohio app th dist  ohio app lexis  gay v of mossberg  sons inc ohio chokan v ford  no   ohio app lexis  th dist oct   mayor v ford motor co  wl  ohio th dist ct app june   loeschner v clark material handling  ohio app lexis  furness v pois  ohio app d  ohio app  pifher v ford motor company  ohio app lexis  furbee v ford motor company  ohio app lexis  national city bank v jim pritz ford inc  ohio app lexis  neff v celanese piping sys  ohio app lexis  cooper v basf inc et al summit county court of common pleas ohio case no cv buynie v airco inc  wl  nj super ad  mceldowney v air products  chemicals inc  mich app lexis  anderson v airco  wl  del super nov    wl  del super june   hurst v american racing equipment inc  tex app lexis  representative litigation national representation of multiple chemical companies and the industry trade association in wrongful death product liability and industry wide liability claims involving occupational and consumer vinyl chloride exposure defense of a putative class action against a leading coatings manufacturer arising out of claimed environmental contamination involving hexavalent chrome in jersey city new jersey national representation of an aftermarket automotive supplier in product liability and contractual disputes national representation of the largest polymer service company in product liability matters multistate representation of a target defendant in a  million damage phase of consumer class action based litigation concerning water heaters defense of an ohio putative consumer class action against a leading beverage maker defense of a putative class action against a leading coatings manufacturer arising out of claimed environmental contamination involving solvent contaminants in louisville kentucky defense of a number of chemical manufacturers in a putative class action arising out of occupational exposure to vinyl chloride at a chemical facility in new jersey defense of a putative consumer class action in ohio against a leading power tool manufacturer defense of a chemical manufacturer in mass action claims for medical monitoring property damage and personal injury arising out of alleged environmental contamination in west virginia defense of a manufacturer in medical monitoring and property damage claims arising out of alleged environmental solvent contamination in groundwater in pennsylvania representation of a leading coatings manufacturer in benzene litigation representation of a multinational chemical company in pesticide application litigation representation of a leading chemicals manufacturer in a number of tce exposure case claiming parkinson’s disease and parkinsonism representation of coatings companies on strategies concerning bpa use and applications representation of a pharmaceutical manufacturing company in an ohio wrongful death action representation of multinational chemical corporation in product liability matters resulting in wrongful death suits representation of multinational electronic supplier in product liability matters representation of multinational electronics entity in commercial disputes over breaches of warranty representation of numerous machine tool manufacturers in product liability matters representation of numerous pesticide manufacturers in product liability matters arising out of chemical exposure representation of various medical device manufacturers in product liability cases ranging from implants to sterilizers statewide representation of a fortune  manufacturer in all premises liability matters representation of handgun manufacturers in various ohio municipal litigation representation of a fortune  manufacturer in multiple jurisdictions for multimillion dollar fire and business interruption losses representation in ohio of various asbestos product manufacturers technology related representation represents court automation software firm in contract negotiation and licensing issues represented software firm in  million sale to publicly traded government consulting firm represents businesstobusiness firm in acquisition of media print and database firm represents fortune  automaker in consumer facing web site compliance issues represents software consulting firms on licensing issues represents startup biotech firm for light manufacturing represents startup supply chain management firm in medical supply field publications “be careful what you wish for revised tsca process slower than industry hoped” thompson hine product liability litigation update february  “social media the internet and electronically stored information esi challenges” national business institute september  “tsca overhaul will have major impact on chemical manufacture  use” thompson hine environmental update june  coauthor “the ongoing antibpa crusade in the united states a disservice to science and consumers” washington legal foundation july   coauthor “rfps afas lpm kpis unpacking the alphabet soup of st century legal service delivery” toxic torts and environmental law seminar defense research institute austin tx “california dtsc finalizes green chemistry playbook” thompson hine green products update april  coauthor “changing times how dukes circumscribes mass toxic tort class certification” thompson hine product liability enewsletter winter  coauthor states take the lead on legislating bpa even where united states  european nations have found bpa safe as currently used thompson hine product liability update march  “suit urges epa to regulate nanosilver remove products from shelves” thompson hine product liability update january  “potential changes to osha’s psm standard  epa’s rmp regulation” thompson hine chemical industry update october  osha seeks comments on proposed changes to process safety management regulations thompson hine chemical industry update january  wva chemical spill prompts dubious regulatory fixes  law january   coauthor “no going back strategies for opposing remand under cafa’s exceptions” washington legal foundation  critical legal issues working paper series dec  and the defense wins · the voice defense research institute august   coauthor “digging deeper mass toxic tort class certification after dukes comcast and amgen” toxic and hazardous substances litigation july  and the defense wins the voice defense research institute february  green products update california proposes new green chemistry regulations thompson hine product liability alert november  bottles cans and bans the latest dispatch from the bpa battlefield for the defense defense research institute march  preventing forum shopping sprees how to be the squeaky wheel on a forum shopping cart for the defense october  the benefits of an extranet for the defense defense research institute january  presentations social media the internet and electronically stored information esi challenges national business institute september  the ins and outs of tsca reform ohio chemistry technology council september  moderator “rfps afas lpm kpis unpacking the alphabet soup of st century legal service delivery” toxic torts and environmental law seminar defense research institute march   austin tx social media use and other complex jury issues national business institute november   on the horizon trends facing the chemical industry thompson hine llp seminar cleveland ohio december   handling rambo litigators in ohio national business institute september  are you covered emerging legal threats and their coverage issues risk international thompson hine llp seminar cleveland december  were the government and we are here to help the neverending storyies of scientific missteps at epa under the iris process whats next in chemical industry regulation litigation and advice thompson hine llp seminar cleveland december  employing effective defense strategies to explain complex science and medical terminology to judges and juries chemical products liability  environmental litigation conference april  bottles cans and bans the latest dispatch from the bpa battlefield defense research institute annual meeting san diego october  winning your first civil trial national business institute cleveland september  strengthening defense positions despite regulatory changes made by the obama administration overcoming preemption hurdles accepting proposed tsca changes and coming to terms with chemical bans american conference institutes chemical products liability and environmental litigation chicago april  chemical regulation and its impact on product liability law  goodyear law conference april  tsca update the toxic substances control act tsca – what are the big threats to chemical manufacturers as congress considers changes ohio chemistry and technology council nd annual conference columbus ohio april  evidence and expert testimony best practices supporting your case cleveland december  best practices in mass complex and toxic tort litigation thompson hine llp seminar cincinnati november  best practices in mass complex and toxic tort litigation thompson hine llp seminar cleveland may  antichemical initiatives chemical bans chemical deselection mandates and the future ohio chemistry technology council annual conference columbus ohio april  trends in litigation association of corporate counsel seminar cleveland july  using high tech tools for litigation a survey of cutting edge technology to assist inhouse counsel acca conference for corporate counsel  washington dc june  emerging trends in liability litigation pricewaterhousecoopers general counsel forum february  techno torts network of trial law firms stamford connecticut july  distinctions litigation star by benchmark litigation    ohio super lawyers    the best lawyers in america®     the burton award for legal achievement  av® preeminent rated by martindalehubbell professional and civicprofessional associations federal bar association northern district of ohio chapter member ohio chemistry technology council octc member defense research institute toxic tort and environmental law  committee chair  and  committee vice chair  seminar program chair corporate counsel roundtable steering committee  international association of defense counsel us law firm group litigation section representative society of chemical manufacturers and affiliates representative ohio association of civil trial attorneys cleveland metropolitan bar association litigation  environmental section ohio oil and gas association ooga member community activities friends of breakthrough schools board member  to present bruce baskincystic fibrosis golf tournament board  to present tournament chairman  newsbenchmark litigation recognizes  thompson hine litigators  practices in three statesnovember  the ongoing antibpa crusade in the united states a disservice to science and consumersjuly  benchmark litigation recognizes  thompson hine litigators and litigation practices in three states december  “no going back strategies for opposing remand under cafa’s exceptions”december  benchmark litigation  recognizes thompson hines litigators  firm receives national and regional recognitionoctober  experts testimony properly excluded woman denied trial on fipronil exposurejuly  thompson hine shortlisted by benchmark litigation as midwest product liability firm of the yearjanuary  benchmark litigation  recognizes thompson hines litigatorsnovember  and the defense wins summary judgment for basffebruary  thompson hine files ohio supreme court brief on behalf of ohio chemistry technology council american chemistry council and polyone corporationfebruary   admissions ohio us court of appeals for the first circuit us court of appeals for the sixth circuit us district court for the district of central illinois us district court for the northern district of ohio us district court for the southern district of ohio contact informationcleveland key center public squarecleveland ohio direct fax educationcase western reserve university school of law jd  order of the coifuniversity of notre dame bba admissions ohio us court of appeals for the first circuit us court of appeals for the sixth circuit us district court for the district of central illinois us district court for the northern district of ohio us district court for the southern district of ohio email disclaimer you must agree to thompson hines terms and conditions set forth in the disclaimer below before submitting any email to us thompson hine llp disclaimer this website provides general information about thompson hine llp for the convenience of visitors to the site the site and the content within it are not intended to establish and their use does not establish an attorneyclient relationship between thompson hine and any visitor information on the website is not legal advice do not send confidential information to any of our lawyers without first obtaining specific authorization this website includes photographs of our lawyers and staff some of the design images and photographs on our website may be of actors depicting fictional scenes statements on this website of prior results do not guarantee a similar outcomeattorney advertisingthis website may be considered attorney advertising in some jurisdictions decline accept your list is empty create pdf atyr pharma announces appointment of timothy p coughlin to its board of directors  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings press release april    pm edt atyr pharma announces appointment of timothy p coughlin to its board of directors san diego apr   globe newswire via comtex  atyr pharma inc quoteszigmancomposite life   a biotherapeutics company engaged in the discovery and development of physiocrinebased therapeutics to address severe rare diseases today announced the appointment of timothy p coughlin to its board of directors mr coughlin served as chief financial officer of neurocrine biosciences from september  to february  mr coughlin brings to the board his extensive background in financial and accounting matters for public companies and leadership experience with highgrowth clinical stage companies in the biotechnology industry this is an exciting time for atyr said mr coughlin atyr has a unique approach to pharmaceutical development given its leadership position in physiocrinebased product biology across three important therapeutic areas i look forward to contributing to atyr potentially bringing these highly innovative products to patients we are incredibly pleased to welcome mr coughlin to our board of directors said john mendlein phd ceo tims industry expertise makes him an excellent addition for atyr as a board member with over a decade in leadership at neurocrine biosciences tims experience will provide valuable guidance as we create longterm value for our stockholders  about timothy p coughlin timothy p coughlin served as chief financial officer of neurocrine biosciences inc from september  to february  where he previously served as vice president controller prior to joining neurocrine in  he was with catholic health initiatives a nationwide integrated healthcare delivery system where he served as vice president financial services mr coughlin also served as a senior manager in the health sciences practice of ernst  young llp and its predecessors from  to  mr coughlin currently serves on the board of directors of retrophin inc and fate therapeutics inc two biotechnology companies where he chairs the audit committees and is also a member of the compensation committee and nominating committee  mr coughlin holds a masters degree from san diego state university and a bachelors degree from temple university and is a certified public accountant in both california and pennsylvania about atyr pharma atyr pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology a newly discovered set of physiological pathways to date the company has generated three innovative therapeutic candidate programs based on its knowledge of physiocrine biology in three different therapeutic areas atyr has built an intellectual property estate to protect its pipeline comprising over  issued patents or allowed patent applications that are owned or exclusively licensed including over  potential physiocrinebased protein compositions atyrs key programs are currently focused on severe rare diseases characterized by immune imbalance for which there are currently limited or no treatment options for more information please visit httpwwwatyrpharmacom  forwardlooking statements this press release contains forwardlooking statements within the meaning of the private litigation reform act  forwardlooking statements are usually identified by the use of words such as anticipates believes estimates expects intends may plans projects seeks should will and variations of such words or similar expressions we intend these forwardlooking statements to be covered by such safe harbor provisions for forwardlooking statements and are making this statement for purposes of complying with those safe harbor provisions these forwardlooking statements including statements regarding the potential of resolaristm or stalaristm the ability of the company to undertake certain development activities such as clinical trial enrollment and the conduct of clinical trials and accomplish certain development goals the timing of initiation of additional clinical trials and of reporting results from our clinical trials and reflect our current views about our plans intentions expectations strategies and prospects which are based on the information currently available to us and on assumptions we have made although we believe that our plans intentions expectations strategies and prospects as reflected in or suggested by those forwardlooking statements are reasonable we can give no assurance that the plans intentions expectations or strategies will be attained or achieved furthermore actual results may differ materially from those described in the forwardlooking statements and will be affected by a variety of risks and factors that are beyond our control including without limitation risks associated with the discovery development and regulation of our physiocrinebased product candidates as well as those set forth in our most recent annual report on form k for the year ended december   and in our other sec filings except as required by law we assume no obligation to update publicly any forwardlooking statements whether as a result of new information future events or otherwise contact mark johnson sr director investor relations mjohnsonatyrpharmacom  copyright c  globenewswire inc all rights reserved quoteszigmancomposite add to watchlist life atyr pharma inc us  us nasdaq     volume  july   p pe rationa dividend yieldna market cap million rev per employeena most popular  the dark side of cruises  cocacola to replace coke zero in us  market snapshot dow ends at record but tech slump weighs on sp  nasdaq  if you can buy only one stock or etf make it this one  barrons buzz how to fix wall street and bankers pay find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest arenault profit leaps but shares decline abelgiums inflation rate picks up pace agerman consumer prices rise faster than expected arussia retaliates to new sanctions by telling us to cut diplomats afrench economy expands  in the second quarter abig six leave border adjustment out of tax principles akids are training to be ceos and spies at these specialized summer camps aamericans are so uncomfortable asking for money that we’ve resorted to this instead aoil pauses ahead of us rig data but  weekly gain in sight a weird things i found out about corporate america in my first  hours aubs credit suisse profits up after strategy shift astudent loan companies to feds tell states to stop regulating us abritishmade seedlip aims to woo the nondrinking crowd aset yourself up to get the most out of retirement aeuropean stocks sell off as ubs falls tech worries weigh aprince william and kate middleton are hiring— though not for these weird five royal family jobs arightmove profit rises on ad sales abank of ireland profit falls to restart dividend ahow do i get a reverse mortgage aus tech stocks shape up for another day of selling after amazon disappoints loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  coughlin timothy p top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active coughlin timothy p • san diego ca how do i update this listing coughlin timothy p is based out of san diego whalewisdom has at least  insider transactions form  in our database for coughlin timothy p summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from coughlin timothy p enter your email address below and choose submit your email cancel contact info coughlin timothy p  el camino real san diego ca     business phone   sec sic codebiological products no disgnostic substances recent sec filings  filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free